Dr.ย Xinliangย Mao
MD, PhD
Professor of Tumour Pharmacology
corporate_fareGuangzhou Medical University, Guangzhou
Xinliang Mao
MD, PhD
Prof. Xinliang Mao is a Professor of Tumour Pharmacology at Guangzhou Medical University, where he leads the Guangdong Key Laboratory of Protein Modification and Degradation. He is internationally recognised for his work on multiple myeloma drug development, with a particular focus on novel small-molecule agents targeting myeloma survival pathways.
Prof. Mao has built a distinguished research career spanning Soochow University and Guangzhou Medical University, accumulating over 115 peer-reviewed publications and more than 3,800 academic citations. His laboratory has identified and characterised a series of novel anti-myeloma compounds targeting the JAK2/STAT3 signalling pathway, the c-Maf/Otub1 deubiquitinase axis, proteasome inhibition, and CDK9-driven transcription. He has maintained active research collaborations with leading international cancer centres including the Princess Margaret Cancer Centre in Toronto. His work is directly relevant to patients with relapsed or refractory myeloma who have exhausted standard treatment lines and are seeking novel therapeutic strategies.
CancerFax can coordinate medical-report review and consultation support for international patients seeking a specialist opinion from Prof. Mao, subject to institutional availability and case acceptance.
Why Consider Prof. Xinliang Mao?
Prof. Mao is one of China's most productive researchers in myeloma pharmacology, with a translational focus that bridges laboratory drug discovery and clinical haematology. Patients with drug-resistant or relapsed myeloma may benefit from his insight into emerging therapeutic targets.
Areas of Specialisation
Translational pharmacology and novel drug development for haematologic malignancies
Prof. Mao's work spans the full translational pipeline from drug target identification through preclinical validation, with a primary focus on multiple myeloma and related haematologic cancers.
Multiple Myeloma Pharmacology
Drug target identification and validation in plasma cell malignancies.
- arrow_rightIdentification of small-molecule STAT3 inhibitors with anti-myeloma activity
- arrow_rightTarget-based high-throughput compound screening
- arrow_rightPreclinical evaluation in myeloma cell lines and xenograft models
- arrow_rightMechanistic study of c-Maf oncogenic transcription factor in myeloma
- arrow_rightTargeting Otub1 and USP7 deubiquitinases to induce c-Maf degradation
- arrow_rightIdentification of natural product-derived compounds disrupting c-Maf stability
Drug Resistance & Novel Agents
Overcoming resistance to standard myeloma therapies through mechanistic research.
- arrow_rightCharacterisation of resistance mechanisms to bortezomib and related agents
- arrow_rightDevelopment of novel proteasome inhibitors with improved selectivity profiles
- arrow_rightPreclinical evaluation of CDK9 inhibitors in myeloma
- arrow_rightInvestigation of MYC/MCL-1 downstream pathways as drug targets
Research Focus & Clinical Approaches
Translational drug development and expert consultation for haematologic malignancies
Prof. Mao's primary contribution is translational โ bridging laboratory drug discovery with haematologic oncology clinical practice, particularly for patients with myeloma resistant to existing therapies.
Novel Drug Development Consultation
Medical OncologyExpert opinion on emerging anti-myeloma agents, including those in preclinical and early clinical development.
Second Opinion โ Myeloma Management
Second OpinionExpert review of myeloma diagnosis, staging, and treatment strategy.
Drug Resistance Assessment
Complex DiseaseSpecialist review of resistance mechanisms in relapsed or refractory myeloma.
Monitoring & Follow-Up Opinion
MonitoringExpert perspective on disease monitoring and response assessment during treatment.
Research & Publications
Peer-reviewed contributions to multiple myeloma pharmacology and drug development
Prof. Mao has published over 115 peer-reviewed articles with more than 3,800 academic citations, spanning novel anti-myeloma drug discovery, drug resistance mechanisms, and translational haematologic oncology.
Prof. Mao's active research into novel myeloma agents means patients with relapsed or drug-resistant disease may gain access to emerging therapeutic insights through a CancerFax-coordinated consultation.
Education & Training
Prof. Mao completed his medical and doctoral training in China and conducted postdoctoral research abroad before building his independent academic career at Soochow University and subsequently Guangzhou Medical University.
Clinical Experience
Prof. Mao has held full professorial appointments for over 15 years across two leading Chinese research universities, building one of China's most productive laboratories in myeloma pharmacology and novel drug development.
Languages & International
Prof. Mao conducts consultations and research communications in the following languages.
CancerFax can coordinate certified medical interpreters for patients who require support in languages beyond Mandarin and English.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Xinliang Mao
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Xinliang Mao's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Xinliang Mao's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Xinliang Mao before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Xinliang Mao's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Xinliang Mao's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Xinliang Mao's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Xinliang Mao
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Mao at Guangzhou Medical University, subject to institutional availability and case acceptance.
Prof. Mao's primary focus is multiple myeloma, including relapsed and refractory cases resistant to standard therapies such as proteasome inhibitors and immunomodulatory drugs. His broader research also covers lymphoma, chronic myeloid leukaemia, and other haematologic malignancies.
Submit your medical reports through CancerFax using the Send Your Reports option. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with the hospital, subject to availability.
A second-opinion request can be submitted through CancerFax with the patient's bone marrow biopsy reports, cytogenetic and FISH results, M-protein data, imaging, and prior treatment history. The final consultation format and availability depend on Prof. Mao's institution.
Prof. Mao's laboratory has specifically investigated resistance mechanisms to proteasome inhibitors and other myeloma agents, and has identified novel therapeutic targets including JAK2/STAT3, c-Maf/deubiquitinase pathways, and CDK9. This research focus is directly relevant to patients whose disease has stopped responding to standard treatments and who are exploring next-line options.
Prof. Mao's work is primarily translational and laboratory-based. Patients interested in access to investigational agents or clinical trials at Guangzhou Medical University should submit their case through CancerFax, and the team will assess current opportunities subject to eligibility and availability.
Connect with Xinliang Mao Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.